Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926 on ClinicalTrials.gov · last registry update 2017-06-14

Stopped early, having planned 14 participants. Completed August 2015. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Alabama at Birmingham
Sponsor type: Other
Enrollment: 14
Started: 2011-02
Primary completion: 2015-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Determine Changes in Bone Resorption Markers During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.

Conditions studied

Type 2 Diabetes Mellitus · Bone Remodeling

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.